Bayer and Université de Sherbrooke Enter License Agreement to Drive Innovation in Dairy Cattle Health

Strategic licensing transaction focuses on advancing a novel vaccine candidate for mastitis, one of the most challenging endemic diseases affecting dairy herds
Leverkusen, Germany, and Quebec, Canada, May 30, 2016 – Bayer and TransferTech Sherbrooke, the corporate entity responsible for commercializing the innovations emerging from the Université de Sherbrooke and its affiliated institutions, have signed a global license agreement to advance a novel vaccine candidate discovered at Université de Sherbrooke in Quebec, Canada, to help protect dairy cattle from mastitis caused by the bacterium Staphylococcus aureus.
More at: